DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

iECURE, a private clinical-stage genome editing company, reported preliminary safety observations fr

Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 35.9% to $7.3 during Tuesday's

PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durably improve

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL

– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL

Also in its updated corporate deck, the Company announced activation of a second clinical site at Wa

Oppenheimer analyst Joseph Thome initiates coverage on Precision BioSciences (NASDAQ:DTIL) with a

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL

Precision BioSciences (DTIL) trades up 10.55% premarket. Bullish moving averages and new data point

- New biopsy data demonstrate thatPBGENE-HBV directly eliminated cccDNA through its primary mechanis

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel

– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in ske

Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.75) per share which missed the

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel

iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs

Jones Trading analyst Catherine Novack assumes Precision BioSciences (NASDAQ:DTIL) with a Buy rat

- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patien

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel

– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel

– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for t

Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates exp

Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates exp

Reached alignment with FDA on endpoints, comparators and sample size for the ongoing OTC-HOPE study

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel

Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a clinical stage gene editing compa

PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeti

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly los

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

  Friday's session saw 225 companies set new 52-week lows.

Companies Reporting Before The Bell • WPP (NYSE:WPP) is projected to report earnings for its first

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

  On Friday, 469 companies hit new 52-week lows.

  On Wednesday, 479 stocks made new 52-week lows.

  Tuesday's morning session saw 84 companies set new 52-week lows.

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for